Metraipolis › archive › dc_ad2f24348b78
Identification of antibody targets associated with lower HIV viral load and viremic control — Europe PMC PMID:39288118
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/39288118
- DOI
- 10.1371/journal.pone.0305976
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T15:34:28.580Z
- SHA-256 of the archived text
bbf9681e77813319944a22fdaf93e06353233301e238b42dc01438e60b064ff9- Stable URL of this page
https://metraipolis.com/documento/dc_ad2f24348b78
How to cite
Identification of antibody targets associated with lower HIV viral load and viremic control — Europe PMC PMID:39288118 — Europe PMC (en), https://europepmc.org/article/MED/39288118 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_ad2f24348b78 (Metraipolis archive dc_ad2f24348b78, sha256 bbf9681e77813319944a22fdaf93e06353233301e238b42dc01438e60b064ff9)
BibTeX
@misc{dcad2f24348b78,
title = {Identification of antibody targets associated with lower HIV viral load and viremic control — Europe PMC PMID:39288118},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/39288118},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_ad2f24348b78; sha256 bbf9681e77813319944a22fdaf93e06353233301e238b42dc01438e60b064ff9},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39288118. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: High HIV viral loads (VL) are associated with increased morbidity, mortality, and on-going transmission. HIV controllers maintain low VLs in the absence of antiretroviral therapy (ART). We previously used a massively multiplexed antibody profiling assay (VirScan) to compare antibody profiles in HIV controllers and persons living with HIV (PWH) who were virally suppressed on ART. In this report, we used VirScan to evaluate whether antibody reactivity to specific HIV targets and broad reactivity across the HIV genome was associated with VL and controller status 1-2 years after infection. Methods: Samples were obtained from participants who acquired HIV infection in a community-randomized trial in Africa that evaluated an integrated strategy for HIV prevention (HPTN 071 PopART). Controller status was determined using VL and antiretroviral (ARV) drug data obtained at the seroconversion visit and 1 year later. Viremic controllers had VLs 2,000 copies/mL at both visits. Both groups had no ARV drugs detected at either visit. VirScan testing was performed at the second HIV-positive visit (1-2 years after HIV infection). Results: The study cohort included 13 viremic controllers and 64 non-controllers. We identified ten clusters of homologous peptides that had high levels of antibody reactivity (three in gag, three in env, two in integrase, one in protease, and one in vpu). Reactivity to 43 peptides (eight unique epitopes) in six of these clusters was associated with lower VL; reactivity to six of the eight epitopes was associated with HIV controller status. Higher aggregate antibody reactivity across the eight epitopes (more epitopes targeted, higher mean reactivity across all epitopes) and across the HIV genome was also associated with lower VL and controller status. Conclusions: We identified HIV antibody targets associated with lower VL and HIV controller status 1-2 years after infection. Robust aggregate responses to these targets and broad antibody reactivity across the HIV genome were also associated with lower VL and controller status. These findings provide novel insights into the relationship between humoral immunity and viral containment that could help inform the design of antibody-based approaches for reducing HIV VL. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2024 (prima pubblicazione 2024-09-17). Identificativi: PMID 39288118 · PMCID PMC11407625 · DOI 10.1371/journal.pone.0305976. Descrittori MeSH principali: Viremia; HIV Infections; HIV Antibodies; Viral Load. Pagina: https://europepmc.org/article/MED/39288118 — https://doi.org/10.1371/journal.pone.0305976. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T15:12:56.242Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.